DIM
BMRN icon

DC Investments Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

DC Investments Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,324
Closed -$410K – 99
2020
Q2 		$410K Buy
+3,324
New +$330K 0.15% 96

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DC Investments Management's BMRN Position: Q3 2020 in Review

DC Investments Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 3,324 shares — an estimated $410K sold.

DC Investments Management first reported a position in BMRN in Q2 2020 and held it in 1 quarter. The position peaked at $410K in Q2 2020. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

  • DC Investments Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • DC Investments Management sold 3,324 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $410K.
  • DC Investments Management first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • DC Investments Management's BioMarin Pharmaceuticals position peaked at $410K in Q2 2020.
  • 496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on DC Investments Management's 13F filing for Q3 2020, filed 4 Nov 2020.